Brand

(redirected from proprietary name)
Also found in: Dictionary, Thesaurus, Medical, Financial, Encyclopedia, Wikipedia.

TO BRAND. An ancient mode of punishment, which was to inflict a mark on an offender with a hot iron. This barbarous punishment has been generally disused.

Mentioned in ?
References in periodicals archive ?
Through the Center for Drug Evaluation and Research (CDER), a review is conducted by the Division of Medication Error Prevention and Analysis (DMEPA) in consultation with the Division of Drug Marketing, Advertising and Communications (DDMAC) to determine the acceptability of the proposed proprietary name. (58) The DMEPA conducts the safety review.
Proprietary drug name approval: taking the duel out of the dual agency process
The name Gimoti was reportedlydeveloped in compliance with the US FDA's Guidance for Industry, Contents of a Complete Submission for the Evaluation of Proprietary Names..
Evoke Pharma awarded conditional US FDA acceptance for proposed brand name for EVK-001
Lyxumia is the proprietary name approved by the European Medicines Agency and other health authorities, concluded the company.
Sanofi's NDA for lixisenatide passes US FDA acceptance for treating adults with type 2 diabetes mellitus (T2DM)
The FDA recently accepted BELBUCA as the proprietary name for (buprenorphine HCl) buccal film.
Endo Pharmaceuticals and BioDelivery Sciences' NDA for BELBUCA buccal film accepted by the US FDA for chronic pain
According to the company, RayVa is the proprietary name for its product candidate for the treatment of Raynaud's phenomenon that is secondary to systemic sclerosis, a circulatory disorder affecting the hands and feet and has no approved therapy in the US.
Apricus Biosciences wins US Patent for RayVa for first-in-class treatment for Raynaud's phenomenon
RayVa is the proprietary name for Apricus' product candidate for the treatment of Raynaud's phenomenon.
Apricus Biosciences wins notice of allowance in the US for patent application for RayVa
A request for proprietary name review for Triferic will be filed with the New Drug Application (NDA) submission, the company said.
Rockwell Medical announces acceptance of proprietary trade name of Triferic by US FDA for investigational iron-delivery drug SFP
Lyxumia is the proprietary name approved by the European Medicines Agency (EMA), Australia and Mexico, and submitted to other health authorities for the GLP-1 RA lixisenatide.
Sanofi reports positive Phase 3 data for Lixisenatide for Type 2 diabetes as a once dally treatment
Under this application, a New Drug Application (NDA) for UMEC/VI (62.5/25mcg and 125/25mcg doses), with the proposed proprietary name ANORO ELLIPTA, has been submitted to the Japanese Ministry of Health, Labour and Welfare (MHLW) as a maintenance bronchodilator treatment to relieve symptoms of obstructive airway disorder due to chronic obstructive pulmonary disease (COPD) (chronic bronchitis and emphysema).
GSK and Theravance submit regulatory application for UMEC/VI in Japan
British pharmaceutical company GlaxoSmithKline (GSK) (LSE:GSK) (NYSE:GSK) said today that it has submitted a Marketing Authorisation Application (MAA) in Europe for albiglutide, with the proprietary name EPERZAN.
GSK files albiglutide MAA in Europe
In addition, the company is preparing to launch lixisenatide in the EU in late Q1 2013 under the proprietary name Lyxumia.
Sanofi announces US FDA's acceptance of lixisenatide NDA for type 2 diabetes mellitus
Both firms have proposed the proprietary name Anoro Ellipta for umeclidinium bromide.
GlaxoSmithKline and Theravance submit regulatory application for umeclidinium bromide

Legal browser ?
Full browser ?